DCGI Permits CMC Vellore to Begin Trials on Mixing of COVID-19 vaccines

The Drugs Controller General of India (DCGI) has approved the Christian Medical College (CMC) Vellore to begin a study on the combination of COVID-19 vaccines, the Centre said on Tuesday. DrRenuSwarup, Secretary of the Department of Biotechnology, said, “A couple of such studies have been initiated,” “We need more scientific data to get more clarity,” she continued.

DrSwarup revealed that the Covid-19 vaccine, developed by the Hyderabad-based Biological E, is in the final stages of testing.

Biological E is expected to submit results for phase 1 and 2 clinical trials for emergency use authorization of its coronavirus vaccine, Corbevax, by the end of September or early October, according to sources.

Central Drugs Standard Control Organisation (CDSCO) Granted Permission

An expert panel of the Central Drugs Standard Control Organisation (CDSCO) on July 29 had recommended granting permission for conducting the study.

The report said that the trial would involve 300 healthy volunteers.

The Indian Council of Medical Research (ICMR) revealed in its study that the combination of Covaxin and Covishield vaccines, the two main vaccines of the Covid vaccination program, conducted on 18 people, had elicited better safety and immunogenicity results.

In the study, ICMR had compared the safety and immunogenicity profile with those individuals who received either Covaxin or Covishield and it showed better results.

Key Finding from the Study

The findings of the study suggested that immunisation with a combination of an adenovirus vector platform-based vaccine followed by an inactivated whole virus vaccine was not only safe but also elicited better immunogenicity.

However, a WHO expert panel last month said that studies on mixing and matching of doses of COVID vaccines required cautious interpretation.

Many other international locations have experimented with having different vaccines in trial mode maximum, prominently the com-cov scientific trial in the UK, which combined Pfizer with AstraZeneca, and the Spanish combivacs trial which again examined the equal vaccine combination. Provinces in Canada have allowed vaccines to be mixed and matched. While the effectiveness of these mixtures isn’t always demonstrated, specialists stated safety turned into not likely to be a chief concern, even though it’d take a totally big pool of volunteers to establish it both way.

Friday, Sputnik V vaccine producers reported, even in limited quantities in India, reported that a process of 50 volunteers in Azerbaijan, who received the Russian and Astrazeneca vaccine, which turned out to be “a security profile high “and not serious adverse events.

For more latest news Click Here

Follow Us
Twitter: @TimesTechPharm1

Leave a Reply

Your email address will not be published. Required fields are marked *